6 known cases. View patent page →
Delaware Hatch-Waxman ANDA action asserting the '724, '725, '424, '219, and '094 patents against Fresenius Kabi USA, LLC; terminated in 2015.
New Jersey Hatch-Waxman ANDA action (ANDA No. 205870) asserting the '724, '725, '424, '219, and '094 patents against Sagent Pharmaceuticals, Inc.; Sagent later settled.
Separate suit by Helsinn against Dr. Reddy's Laboratories asserting U.S. 8,729,094 and U.S. 9,066,980; related to the D.N.J. palonosetron litigation.
FDA's NDA review document states a lawsuit was filed on July 7, 2014 for patent 8729094. Helsinn sought a preliminary injunction based on claim 4 of the '094 patent, which was denied; Teva later launched generic palonosetron at-risk on 2018-03-23.
Complaint contains a distinct Count V for infringement of the '094 patent, alleging Hospira's ANDA No. 207005 (0.25 mg/5 mL and 0.075 mg/1.5 mL) infringed the '094 patent.
IPR petition filed by Dr. Reddy's Laboratories, Ltd. et al. against Helsinn challenging claims 22–27 and 30 of US 8,729,094. Institution was denied and the proceeding was terminated on 2015-10-14 following a joint motion to terminate after settlement.